British Journal of Clinical Pharmacology,
Год журнала:
2023,
Номер
89(7), С. 2332 - 2333
Опубликована: Май 3, 2023
It
is
evident
that
polypharmacy
among
older
adults
results
in
increased
cumulative
anticholinergic
exposure
and
several
adverse
outcomes.
We
read
with
interest
congratulate
Hilmer
et
al.
on
their
multicentre
cohort
study
Australia,
investigating
the
association
between
sedative
medication
The
authors
conclude
potentially
inappropriate
medications
(PIMS)
drug
burden
index
(DBI)
are
significantly
associated
risks
of
fall
delirium.1
would
like
to
share
our
experience
from
United
Kingdom
where
a
known
growing
phenomenon
effects
adults.2
investigated
potential
confounding
(ACB)
hospitalized
fall.
prospectively
evaluated
411
consecutive
patients
aged
≥65
years
(mean
age
83.8
±
8.0
years:
40.6%
male)
admitted
acutely
hospital.
Pharmacological
reconciliation
was
carried
out
by
hospital
pharmacists
utilizing
national
patient
database:
NHS
Summary
Care
Record,
which
contains
all
regular
acute
prescriptions.
Incidence
(defined
as
prescription
≥5
oral
medications),
ACB
score
(http://www.acbcalc.com/)
Charlson
Comorbidity
Index
(CCI)
were
recorded
compared
or
without
further
polypharmacy,
summative
score,
CCI,
falls
risk.
Overall
incidence
group
80.8%,
consistent
previous
epidemiology
studies.3
Polypharmacy
76.3%
88.0%,
respectively.
0,
1,
2
≥3
38.7%,
20.9%,
14.6%
25.8%,
On
multivariate
analysis,
(OR
=
1.030,
[1.000;
1.050],
P
0.049),
1.150,
[1.020;
1.290],
0.025),
2.140,
[1.190;
3.870],
0.012)
but
not
CCI
0.920,
[0.810;
1.040],
0.172)
higher
rate
(Table
1).
linear
regression
an
3
0
have
>50%
chance
falling.
also
found
fall,
29.8%
had
drug-related
orthostatic
hypotension,
24.7%
bradycardia,
37.3%
prescribed
centrally
acting
drugs
12.0%
taking
hypoglycaemic
agents.
Our
complements
findings
other
recent
studies
suggesting
risk
adults.2,
4,
5
data
demonstrated
presence
each
unit
rise
stronger
effect
increasing
comorbidities.
modifiable
factors,
strongly
support
deprescribing
when
possible
prevent
improve
outcomes
adults.6,
7
Further
required
clinical
benefits
its
feasibility
setting.
None.
Aging Medicine,
Год журнала:
2023,
Номер
6(2), С. 116 - 123
Опубликована: Апрель 5, 2023
Polypharmacy
is
a
growing
phenomenon
associated
with
adverse
effects
in
older
adults.
We
assessed
the
potential
confounding
of
cumulative
anticholinergic
burden
(ACB)
patients
who
were
hospitalized
falls.
Mental
disorders
are
prevalent
among
older
adults,
often
leading
to
the
use
of
multiple
medications,
many
with
anticholinergic
properties.
Polypharmacy,
common
in
this
population,
is
a
major
contributor
burden,
which
linked
cognitive
and
physical
decline.
This
study
investigates
relationship
between
polypharmacy
burden
across
seven
scales
elderly
patients
attending
psychiatric
outpatient.
Study
was
conducted
at
psychiatry
outpatient
clinic
All
India
Institute
Medical
Sciences,
Rishikesh,
India,
from
December
2021
March
2023.
Elderly
(aged
≥
60
years)
who
were
on
least
one
psychotropic
medication
had
primary
working
diagnosis
illness
included.
including
antidepressants,
antipsychotics,
mood
stabilizers,
hypnotics,
evaluated.
Anticholinergic
calculated
by
respective
tools.
Univariate
analysis
adopted
determine
factors
that
may
affect
polypharmacy.
included
1165
aged
years.
The
prevalence
20.43%
(n
=
238).
Clonazepam
364,
17.28%),
escitalopram
197,
9.35%),
metformin
165,
7.83%),
sertraline
141,
6.69%),
mirtazapine
129,
6.12%),
lorazepam
110,
5.22%)
most
frequently
prescribed
drugs.
demonstrated
all
risk
assessment
closely
correlated
polypharmacy,
strongest
association
observed
for
Load
Scale
(ALS)
(Odds
Ratio
4.3;
p
<
0.001).
Polypharmacy
also
positively
associated
adverse
drug
reactions
1.81;
95%
Confidence
Interval
1.27–2.56).
cohort
high,
95.1%
1108)
experiencing
significant
burden.
Adverse
events
stronger
correlation
ALS
scores
than
other
adults.
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Фев. 20, 2025
This
study
was
aimed
to
examine
the
prevalence
and
associations
between
multimorbidity,
polypharmacy,
Falls
Risk
Increasing
Drugs
use
(FRIDs),
Anti
Cholinergic
Burden
(ACB),
adverse
health
outcomes
in
older
adults
attending
medical
clinics.
A
cross-sectional
conducted
among
704
clinics
four
tertiary
care
hospitals.
The
mean
(SD)
age
of
participants
73
(5.5)
years,
majority
were
females
(58.7%).
Patients
305
(43.5%)
reported
at
least
one
fall
after
65
while
220
(31.3%)
falls
previous
12
months
90
(12.8%)
recurrent
falls.
multimorbidity
77.4%
polypharmacy
seen
51.2%.
FRID
70.5%
patients
higher
ACB
5.4%.
Multimorbidity,
FRIDs
not
associated
with
negative
outcome
(p
>
0.05).
Polypharmacy,
however,
high
<
0.001).
highlights
a
people
clinical
settings.
However,
drugs
indicate
that
these
relationships
are
complex,
potentially
influenced
by
other
factors
such
as
poor
drug
compliance,
which
can
lead
Abstract
Background
Medications
with
potent
anticholinergic
properties
have
well-documented
adverse
effects.
A
high
cumulative
burden
may
arise
from
the
concurrent
use
of
multiple
medications
weaker
We
sought
to
identify
patterns
and
associated
patient
characteristics.
Methods
identified
patients
aged
≥
65
who
filled
1
medication
effects
in
2019
had
a
Anticholinergic
Burden
score
(ACB)
4
(i.e.,
burden)
large
US
health
insurer.
classified
based
on
how
they
attained
burden,
as
follows:
1)
only
filling
strong
or
moderate
ACB
=
2
3,
“moderate/strong”),
2)
lightly
1,
“light/possible”),
3)
any
combination
(“mix”).
used
multinomial
logistic
regression
assess
association
between
measured
characteristics
membership
three
classifications,
using
moderate/strong
group
referent.
Results
In
total,
83,286
eligible
were
(mean
age:
74.3
years
(SD:7.1),
72.9%
female).
Of
these,
4.5%
strong/moderate
anticholinergics,
4.3%
light/possible
rest
mix
(91.2%).
Within
mixed
group,
64.3%
fills
for
while
35.7%
anticholinergics.
Compared
anticholinergics
more
likely
be
older
(adjusted
Odds
Ratio
[aOR]
per
1-unit
1.06,
95%CI:
1.05–1.07),
less
female
(aOR:
0.56,
0.50–0.62
vs.
male),
comorbidities
(e.g.,
heart
failure
aOR:
3.18,
2.70–3.74
depression
1.20,
1.09–1.33
no
comorbidity),
visited
fewer
physicians
(aOR
change:
0.98,
0.97–0.98).
Patients
1.02,
1.02–1.03)
0.89,
0.82–0.97
male)
compared
those
Conclusion
Most
adults
accumulated
through
rather
than
being
major
drivers
overall
burden.
These
insights
inform
interventions
improve
prescribing
adults.
Middle East Current Psychiatry,
Год журнала:
2024,
Номер
31(1)
Опубликована: Апрель 29, 2024
Abstract
Background
Potentially
inappropriate
medications
(PIMs)
are
defined
as
drugs
whose
adverse
effects
outweigh
the
benefits
or
when
more
efficacious
alternatives
present.
This
study
aims
to
assess
overall
prevalence
of
PIMs
according
Beers
2019
and
2023
among
older
adult
patients
with
serious
mental
illnesses
(such
schizophrenia),
factors
associated
while
examining
difference
between
two
versions.
Method
cross-sectional
included
chronic
aged
65
years
above,
hospitalized
at
Psychiatric
Hospital
Cross
(Lebanon),
taking
least
one
medication
daily.
Sociodemographic
characteristics,
medications,
clinical
information
were
obtained
from
patients’
medical
records.
SPSS
version
26
was
used
for
data
analysis.
Descriptive
statistics
describe
independent
variables,
bivariate
analysis
associations
PIM
use
different
factors.
A
two-tailed
p
value
<
0.05
considered
statistically
significant.
Results
Ninety-seven
a
mean
age
71.21
(±
4.63)
years.
52.6%
female.
44.3%
on
polypharmacy
(5–9
medications).
97.9%
had
both
versions
majority
being
anticholinergics
(84.5%).
Polypharmacy
significantly
correlated
use.
stay
length
presence
comorbid
neurological
disorders
negatively
Conclusion
extremely
prevalent
psychiatric
patients.
Raising
awareness
physicians
criteria
making
them
mandatory
could
help
diminish
this
vulnerable
population.
Heliyon,
Год журнала:
2024,
Номер
10(10), С. e30635 - e30635
Опубликована: Май 1, 2024
This
study
aimed
to
evaluate
the
prevalence
of
polypharmacy,
presence
potentially
inappropriate
medications
and
related
factors
in
older
adults
receiving
palliative
care.
cross-sectional
descriptive
was
performed
213
patients
who
were
served
from
care
services.
Mini
Nutritional
Assessment-Short
Form,
Katz
Activities
Daily
Living
Scale
Charlson
Comorbidity
Index
applied.
Polypharmacy
defined
as
use
5
or
more
medicines
while
10
considered
hyper-polypharmacy.
PIM
assessed
according
TIME-to
START
STOP
criteria.
A
total
included,
mean
age
78.00
±
9.08
years.
present
59.2
%
hyper-polypharmacy
10.8
%.
There
a
statistically
significant
correlation
between
polypharmacy
marital
status,
history
falls,
mid-upper
arm,
calf
circumference
(p
=
0.017,
p
0.022,
0.010,
0.003,
respectively).
The
rate
medication
cardiovascular
system,
gastrointestinal
analgesics,
musculoskeletal
nervous
system
drugs
high.
at
least
one
56.3
adults.
PIMs
18.3
TIME-to-START
criteria
48.4
TIME-to-STOP
higher
TIME
group
with
than
non-polypharmacy
<
0.001).
is
high
could
increase
use.
may
be
helpful
reducing
Therapeutic Advances in Psychopharmacology,
Год журнала:
2023,
Номер
13
Опубликована: Янв. 1, 2023
The
evidence
for
the
risks
associated
with
anticholinergic
agents
has
grown
considerably
in
last
two
decades.
Not
only
are
they
causing
peripheral
side
effects
such
as
dry
mouth,
blurred
vision
and
constipation,
but
can
also
cause
central
cognitive
impairment;
more
recently,
have
consistently
been
linked
an
increased
risk
of
dementia
death
older
people.
This
paper
reviews
associations
mortality
dementia.
Autism Research,
Год журнала:
2023,
Номер
17(4), С. 852 - 867
Опубликована: Дек. 18, 2023
Many
commonly
used
prescription
and
over-the-counter
medicines
have
potent
anticholinergic
(AC)
effects.
Among
older
adults,
AC
medications
are
associated
with
cognitive
impairment
risk
for
disorders,
including
Alzheimer's
disease.
Collectively,
the
impact
of
is
known
as
burden
(ACB).
Because
high
rates
co-occurring
medical
psychiatric
conditions,
autistic
adults
may
exposure
and,
thus,
experience
elevated
ACB.
However,
no
research
has
characterized
or
examined
its
associations
outcomes
in
adults.
Autistic
(40-83
years)
recruited
via
Simons
Powering
Autism
Research's
(SPARK)
Research
Match
service
self-reported
their
medication
use
(N
=
415)
memory
complaints
382)
at
Time
(T)1.
At
T2,
2
years
later,
a
subset
T1
participants
197)
on
decline
cognition.
Medications
were
coded
using
two
scales
potency.
A
proportion
(48.2%-62.9%,
depending
upon
potency
scale)
reported
taking
least
one
effects,
20.5%
to
26.5%
clinically-relevant
levels
(potency
≥3).
After
controlling
birth-sex,
age,
hierarchical
linear
regression
models
showed
total
ACB
scores
values
≥3
predicted
greater
complaints.
Logistic
that
follow-up
later.
Understanding
medications-including
potentially
earlier
polypharmacy-and
impacts
cognition
(e.g.,
dementia
risk)
warranted.